Helicos Reiterates Dx Strategy as Product Revenues, Cash Dry Up

As of Aug. 11, Helicos held $3.7 million in cash and cash equivalents — down from $6.2 million as of June 30. The company said that it will need to raise "significant additional capital" before the end of the third quarter in order to continue operations.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.